Christophe A Girard
Overview
Explore the profile of Christophe A Girard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rovera C, Berestjuk I, Lecacheur M, Tavernier C, Diazzi S, Pisano S, et al.
Cancer Res
. 2022 May;
82(9):1774-1788.
PMID: 35502542
Significance: Communication between dedifferentiated melanoma cells and lymph node fibroblasts reprograms the biomechanical properties of the premetastatic lymph node niche to promote tumor invasion. See related commentary by Lund, p....
2.
Diazzi S, Baeri A, Fassy J, Lecacheur M, Marin-Bejar O, Girard C, et al.
EMBO Mol Med
. 2022 Feb;
14(3):e15295.
PMID: 35156321
Lineage dedifferentiation toward a mesenchymal-like state displaying myofibroblast and fibrotic features is a common mechanism of adaptive and acquired resistance to targeted therapy in melanoma. Here, we show that the...
3.
Berestjuk I, Lecacheur M, Carminati A, Diazzi S, Rovera C, Prodhomme V, et al.
EMBO Mol Med
. 2021 Dec;
14(2):e11814.
PMID: 34957688
Resistance to BRAF/MEK inhibitor therapy in BRAF -mutated advanced melanoma remains a major obstacle that limits patient benefit. Microenvironment components including the extracellular matrix (ECM) can support tumor cell adaptation...
4.
Lecacheur M, Girard C, Deckert M, Tartare-Deckert S
Med Sci (Paris)
. 2020 Nov;
36(11):961-965.
PMID: 33151853
No abstract available.
5.
Girard C, Lecacheur M, Ben Jouira R, Berestjuk I, Diazzi S, Prodhomme V, et al.
Cancer Res
. 2020 Mar;
80(10):1927-1941.
PMID: 32179513
Aberrant extracellular matrix (ECM) deposition and stiffening is a physical hallmark of several solid cancers and is associated with therapy failure. BRAF-mutant melanomas treated with BRAF and MEK inhibitors almost...
6.
Seitz-Polski B, Dolla G, Payre C, Girard C, Polidori J, Zorzi K, et al.
J Am Soc Nephrol
. 2015 Nov;
27(5):1517-33.
PMID: 26567246
The phospholipase A2 receptor (PLA2R1) is the major autoantigen in idiopathic membranous nephropathy. However, the value of anti-PLA2R1 antibody titers in predicting patient outcomes is unknown. Here, we screened serum...
7.
Girard C, Seitz-Polski B, Dolla G, Augert A, Vindrieux D, Bernard D, et al.
Med Sci (Paris)
. 2014 Jun;
30(5):519-25.
PMID: 24939538
PLA2R1 is a large transmembrane receptor of 180-kDa that belongs to the superfamily of C-type lectins. It was discovered because of its high affinity for secreted phospholipases A2 (sPLA2), enzymes...
8.
Vindrieux D, Augert A, Girard C, Gitenay D, Lallet-Daher H, Wiel C, et al.
Cancer Res
. 2013 Sep;
73(20):6334-45.
PMID: 24008317
Little is known about the physiological role of the phospholipase A2 receptor (PLA2R1). PLA2R1 has been described as regulating the replicative senescence, a telomerase-dependent proliferation arrest. The downstream PLA2R1 signaling...
9.
Augert A, Vindrieux D, Girard C, Le Calve B, Gras B, Ferrand M, et al.
Free Radic Biol Med
. 2013 Sep;
65:969-977.
PMID: 23994771
Little is known about the biological functions of the phospholipase A2 receptor (PLA2R1) except that it has the ability to bind a few secreted phospholipases A2 (sPLA2's). We have previously...
10.
Ait-Oufella H, Herbin O, Lahoute C, Coatrieux C, Loyer X, Joffre J, et al.
Arterioscler Thromb Vasc Biol
. 2013 Jan;
33(3):466-73.
PMID: 23349189
Objective: Several secreted phospholipases A2 (sPLA2s), including group IIA, III, V, and X, have been linked to the development of atherosclerosis, which led to the clinical testing of A-002 (varespladib),...